| 产品描述： | Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes |
| 靶点： |
5-Lipoxygenase:4.7 μM (IC50);Lipoxygenase |
| 体内研究： |
Malotilate (100 mg/kg; p.o.; daily for 3 days) treatment in rats with hypocholesterolemia results in a rapid normalization of lowered serum cholesterol |
| 参考文献： |
1. Matsuda Y, et al. Effects of malotilate on alcoholic liver injury in rats. Alcohol Clin Exp Res. 1988;12(5):665-670. 2. Vermeer MA, Wilson JH, Zijlstra FJ, Vincent JE. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells. Agents Actions. 1989;26(1-2):252-253. 3. Poeschl A, et al. Malotilate reduces collagen synthesis and cell migration activity of fibroblasts in vitro. Biochem Pharmacol. 1987;36(22):3957-3963. 4. Zijlstra FJ, et al. Differential effects of malotilate on 5-, 12- and 15-lipoxygenase in human ascites cells. Eur J Pharmacol. 1989;159(3):291-295. 5. Wakasugi J, et al. Action of malotilate on reduced serum cholesterol level in rats with carbon tetrachloride-induced liver damage. Jpn J Pharmacol. 1985;38(4):391-401. |
| 溶解性： |
DMSO : ≥ 100 mg/mL (346.76 mM) |
| 保存条件： |
2-8℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.468 ml |
17.338 ml |
34.676 ml |
| 5 mM |
0.694 ml |
3.468 ml |
6.935 ml |
| 10 mM |
0.347 ml |
1.734 ml |
3.468 ml |
| 50 mM |
0.069 ml |
0.347 ml |
0.694 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京